Company Drug

Sino Biopharm’s TQB3205 Wins NMPA Approval – First China-Developed Pan-KRAS Inhibitor Enters Clinic for Advanced Cancers

By Fineline Cube #Chia Tai Tianqing Pharmaceutical #Clinical trial approval / initiation #HKG: 1177 #Sino Biopharmaceutical
Sino Biopharm's TQB3205 Wins NMPA Approval – First China-Developed Pan-KRAS Inhibitor Enters Clinic for Advanced Cancers

Sino Biopharmaceutical Limited (HKG: 1177) announced that TQB3205, an orally administered Pan-KRAS inhibitor independently developed by subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ), has received first-time NMPA clinical trial approval for the treatment of advanced malignant tumors. The novel small molecule achieves high-affinity binding with various KRAS mutant proteins, blocking SOS1-mediated nucleotide exchange and suppressing ERK phosphorylation downstream of KRAS, representing a next-generation approach to targeting the historically undruggable KRAS oncogene across multiple mutation subtypes.

Regulatory Milestone

ItemDetail
AgencyNational Medical Products Administration (NMPA)
Approval TypeFirst-time clinical trial authorization (IND)
ProductTQB3205
Drug ClassOrally administered Pan-KRAS inhibitor (small molecule)
IndicationAdvanced malignant tumors
DeveloperChia Tai Tianqing Pharmaceutical Group (CTTQ) – Sino Biopharmaceutical subsidiary (HKG: 1177)
Development StatusFirst China-developed Pan-KRAS inhibitor to enter clinical trials
Approval Date10 Mar 2026

Drug Profile & Mechanism

AttributeTQB3205 Specification
Target ClassPan-KRAS (multiple KRAS mutant proteins)
Binding MechanismHigh-affinity binding with various KRAS mutant proteins
Molecular ActionInhibits SOS1-mediated KRAS nucleotide exchange
Downstream EffectSuppresses ERK phosphorylation (MAPK pathway blockade)
Clinical OutcomeInhibits proliferation of KRAS mutant tumor cells; target-level anti-tumor effects
RouteOral administration
Innovation ClassNext-generation KRAS targeting (beyond G12C-specific inhibitors)

Scientific Rationale:

  • KRAS Mutations: Present in ~25% of all cancers; G12C, G12D, G12V, G13D subtypes drive oncogenesis
  • SOS1 Inhibition: Blocks guanine nucleotide exchange factor (GEF) activity → traps KRAS in inactive GDP-bound state
  • Pan-KRAS Advantage: Addresses multiple mutant alleles vs. single-mutation inhibitors (sotorasib, adagrasib limited to G12C)

Strategic Context & Market Opportunity

FactorImplication
KRAS Market EvolutionSotorasib/adagrasib (G12C only) approved 2021-2022; limited by narrow mutation coverage; resistance common
Pan-KRAS Unmet NeedG12D (pancreatic, colorectal) and other mutations lack effective targeted therapy; TQB3205 addresses broader population
China InnovationFirst domestic Pan-KRAS inhibitor validates Sino Biopharm/CTTQ discovery capabilities; global competitiveness
Oral ConvenienceSmall molecule oral vs. injectable biologics; improved patient compliance
Combination PotentialSOS1 inhibition synergistic with MEK, EGFR, or immunotherapy in KRAS-driven tumors

Competitive Landscape

CompetitorProductMechanismMutation CoverageStatusTQB3205 Differentiation
AmgenLumakras (sotorasib)KRAS G12C inhibitorG12C onlyApproved (NSCLC, colorectal)Pan-KRAS vs. single mutation; addresses resistance
Mirati/BMSKrazati (adagrasib)KRAS G12C inhibitorG12C onlyApproved (NSCLC)Broader mutation coverage; SOS1 mechanism
Revolution/SanofiRMC-6236RAS(ON) inhibitor (pan-RAS)Multiple RAS isoformsPhase I/IITQB3205 KRAS-specific vs. pan-RAS; potentially better tolerability
Sino Biopharm/CTTQTQB3205Pan-KRAS inhibitor (SOS1-mediated)Multiple KRAS mutantsPhase I-readyFirst China-developed; oral; SOS1 mechanism

Development Outlook

PhaseTimelineObjectives
Phase I2026-2027Safety, tolerability, MTD; pharmacokinetics; biomarker-defined KRAS mutant enrollment
Phase II2027-2029Efficacy signals in pancreatic, colorectal, lung cancers; mutation-specific cohorts
Phase III2029-2031Registrational studies vs. chemotherapy in KRAS G12D pancreatic cancer (high unmet need)
Global Strategy2028+U.S./EU IND filing; partnership discussions for ex-China rights; combination study initiation

Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development timelines, Pan-KRAS mechanism validation, and competitive positioning for TQB3205. Actual results may differ due to KRAS biology complexity, SOS1 inhibition tolerability, and competitive dynamics with G12C inhibitors and emerging pan-RAS approaches.-Fineline Info & Tech

Related Post

Company Drug

Changchun GeneScience’s GenSci128 Wins FDA Orphan Drug Designation – TP53 Y220C Reactivator Targets Pancreatic Cancer

Fineline Cube
Company

Sandoz Forms Global Biosimilars Unit – Metzger-Led Division Targets Accelerated Portfolio Growth

Fineline Cube
Company Deals

Eli Lilly Commits $3 Billion to China Manufacturing – Orforglipron Production Capacity and Local Supply Chain Expansion

Fineline Cube

You Missed

Company Drug

Changchun GeneScience’s GenSci128 Wins FDA Orphan Drug Designation – TP53 Y220C Reactivator Targets Pancreatic Cancer

Company Drug

Sino Biopharm’s TQB3205 Wins NMPA Approval – First China-Developed Pan-KRAS Inhibitor Enters Clinic for Advanced Cancers

Company

Sandoz Forms Global Biosimilars Unit – Metzger-Led Division Targets Accelerated Portfolio Growth

Company Deals

Eli Lilly Commits $3 Billion to China Manufacturing – Orforglipron Production Capacity and Local Supply Chain Expansion